A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Cancer
Multiple Myeloma

For Medical Professional
Results
Download
Print

Basic Details

Sponsor Genentech, Inc.

Phase Phase 1

Study Identifier NCT05243342, GO43073

Condition Multiple Myeloma

Official Title A Phase Ib, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma

Study Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity (ADCC) in participants with relapsed or refractory (R/R) MM who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

Eligibility Criteria

Gender

All

Age

≥18 Years

Healthy Volunteers

Inclusion Criteria

Life expectancy of at least 12 weeks
Measurable disease, as defined by the protocol
Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody
Best response of stable disease or better with at least one prior anti-CD38 monoclonal antibody containing line of treatment

Exclusion Criteria

Any anti-cancer therapy within 3 weeks prior to initiation of study treatment, with exceptions defined by the protocol
Prior allogeneic stem cell or solid organ transplantation
Autologous stem cell transplantation within 100 days prior to initiation of study treatment
Significant cardiovascular disease
Known clinically significant liver disease
Active or history of autoimmune disease or immune deficiency
Known active infection requiring IV anti-microbial therapy within 14 days prior to first study drug administration
Primary or secondary plasma cell leukemia
Current CNS involvement by MM
Other protocol defined inclusion/exclusion criteria may apply

The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Results Disclaimer

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Basic Details

Study Summary

Eligibility Criteria

What is Clinical Research?

Study results

LPS GO43073 Final Results April 2025 USA English (PDF, 0.1 MB)

LPS GO43073 Final Results April 2025 Danish (PDF, 0.1 MB)

LPS GO43073 Final Results April 2025 Norwegian (PDF, 0.1 MB)

LPS GO43073 Final Results April 2025 Spanish (PDF, 0.1 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

For the latest version of this information please go to www.forpatients.roche.com